Project Grant R44DK139886
Award Date
7/25/24
Completion Date
6/30/25
Dollars Obligated
$649K
Similar Awards
This $578,060 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to study a potential new enhancer region that activates the UCP1 gene, which is critical for thermogenesis and energy expenditure. The research will examine how this enhancer functions to increase UCP1 transcription, as well as assess its impact on thermogenesis, adiposity, and...
This Project Grant award, totaling $2,060,811, was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award aims to explore the role of Activin Type II Receptor (ACTRII) signaling in regulating muscle hypertrophy, obesity, and weight loss, particularly in combination with GLP-1/GIP receptor agonists. The research will investigate the systemic effects of ACTRII...
This federal Project Grant award, valued at $450,000.00 and awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to elucidate the roles of the lysine acetyltransferase KAT8 in adipocyte function and its impact on lipoatrophy and systemic insulin resistance. The long-term objective is to understand how adipocyte KAT8 contributes to adipose tissue function and...
This $800,000 federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), will support research at Beth Israel Deaconess Medical Center, Inc. (Bidmc) to develop new combinatorial pharmacology approaches for regulating multiple neuron types in the brain to effectively promote satiety and reduce body weight in mouse models of obesity. The research aims to...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $107,250 to the University of Oklahoma Health Sciences Center Division to conduct research on the role of NR2F2 in beige adipogenesis and its potential to mitigate childhood obesity risk. The award will fund investigations into how early-life exposure to omega-6 fatty acids impacts adipose stem cell fate and beige...
The federal Project Grant award R21DK138178 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research) to Georgia State University Research Foundation Inc. The $418,560 award supports research to evaluate the therapeutic potential of a new orally active small molecule in obesity-linked diabetic models. Key objectives include analyzing the pharmacokinetic profiles of the new molecule,...
This Project Grant award of $659,199 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to investigate a novel pathway by which hepatocyte-derived GDF15 improves obesity-associated insulin resistance independent of body weight loss and GDF15 receptor signaling. The research aims to characterize the structural basis and functional consequences of GDF15...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $582,825 Project Grant under CFDA 93.847 (Diabetes, Digestive, and Kidney Diseases Extramural Research) to Epic Nutrition For Y LLC located in Troy, MI. The project aims to develop a novel probiotic strain, Clostridium cochlearium 2316 (CC), as a safe, long-term, and sustainable dietary supplement/medical food for managing obesity and insulin resistance. The grant will fund critical toxicity and safety...
This $1,145,486 federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to develop novel peripherally acting CB1 neutral antagonists for the treatment of diabetic kidney disease (DKD). The awardee, Makscientific LLC, a for-profit R&D company, will design and synthesize new analogs of compound AM6588 to improve potency, selectivity, oral...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) provides $594,547 to the University of California, Davis to develop and characterize an orally delivered nanodrug designed to compensate for the shortage of specific microbial metabolite-regulated signaling in liver and colon cancer patients. The nanodrug, named PRORA, combines a histone deacetylase...